Search
forLearn
5 / 801 resultslearn Clascoterone
a novel topical treatment that inhibits DHT on androgen receptors
learn Climbazol
learn Clotrimazole
learn Beclomethasone
Research
5 / 14 resultsresearch 0951 Breezula, a clinical stage topical anti-androgen, promotes dermal papilla inductivity and reduces IL-6 secretion in balding skin samples ex vivo
Breezula® may be more effective than Minoxidil in promoting hair growth by reducing a hair growth inhibitor.
research Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
research New drugs under investigation for the treatment of alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Industry update: the latest developments in the field of therapeutic delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research Treat androgenetic alopecia with antiandrogens, as well as other pharmacological and non-pharmacological interventions
Use antiandrogens and other treatments for hair loss.
Community Join
5 / 380 resultscommunity Breezula is a good alternative
Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.
community Breezula Phase III 12-Month Data Released by Cosmo Pharma
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
community Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
community Cassiopea Announces Very Positive Interim Analysis Phase 2 Results for Breezula® (Clascoterone) in Treating Androgenetic Alopecia
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.